This undated photo provided by Acadia Pharmaceuticals Inc. shows a bottle of Nuplazid, a drug that was tested for treating psychosis related to dementia
===================================================================
Posted on 12/05/2019 7:04:01 AM PST by Red Badger
If approved, it could not only help people with Parkinson's but also Alzheimer's.
A drug that curbs delusions in Parkinson's patients did the same for people with Alzheimer's and other forms of dementia. That's the result of a study in which the benefit was so clear, the trial was stopped early.
If regulators agree, the drug -- pimavanserin -- could become the first new medicine for Alzheimer's in nearly two decades. It's sold under the brand name Nuplazid by Acadia Pharmaceuticals Inc.
About 8 million Americans have dementia, and up to 30% develop psychosis. The Associated Press reports pimavanserin targets the hallucinations which often lead to anxiety, aggression, and physical and verbal abuse. The drug blocks a brain chemical that spurs delusions.
The results presented today are an important advance for patients and caregivers who struggle with the burden of dementia-related psychosis where no FDA-approved treatment is currently available,” said Dr. Jeffrey Cummings of the Cleveland Clinic Lou Ruvo Center for Brain Health in a statement. “Reducing the risk of relapse of psychotic symptoms by this magnitude is an important and meaningful outcome as these are serious events which could lead to poor patient outcomes and a significant increase in caregiver burden and distress.”
(Excerpt) Read more at khou.com ...
This undated photo provided by Acadia Pharmaceuticals Inc. shows a bottle of Nuplazid, a drug that was tested for treating psychosis related to dementia
===================================================================
This is great! Will it help cure Democrats?
I wonder if it is effective for climate alarmists and Trump Derangement Syndrome sufferers?
There is no cure for that.
My mom (98) uses Seroquel and I am astonished at how well it has worked for her. At 98, her doctor diagnosed her with bi-polar and dementia (it’s been a rough ride for all of us since we were really small), but this drug has brought out the person I always knew she was. She has delusions, hysteria...you name it.
Excuse me...she HAD hysteria, delusions. No longer.
Maybe, but there already is a drug for that...........Potassium cyanide..............
Nope. They are highly resistant organisms.
Good news and GREAT humor! BUMP!
Ping to the Fanboys.
Never let it be said I didn’t try to help.
JUST IN TIME!!
For you ?...................
Pay special attention to the contraindications/precautions and drug intereactions sections. Anyone elderly on this better have a very good doc.
My wonderful daughter-in-law is a nurse. She was practicing her geriatric interviews on me:
DIL: Do you ever suffer from delusions?
Me: No, I thoroughly enjoy them . . . (bat, bat, bat)
Psychological projection is a defense mechanism people subconsciously employ in order to cope with difficult feelings or emotions. Psychological projection involves projecting undesirable feelings or emotions onto someone else, rather than admitting to or dealing with the unwanted feelings.Nov 15, 2017
Contraindications & Precautions:
General Information
Pimavanserin is contraindicated in patients with a history of a hypersensitivity reaction to pimavanserin or any of its components. Reactions have included rash, urticaria, tongue swelling, circumoral edema, and throat tightness.
Alcoholism, bradycardia, cardiac arrhythmias, cardiac disease, coronary artery disease, diabetes mellitus, females, heart failure, hypertension, hypocalcemia, hypokalemia, hypomagnesemia, long QT syndrome, malnutrition, myocardial infarction, QT prolongation, thyroid disease
Pimavanserin may cause QT prolongation and should be avoided in patients with cardiac disease or having other risk factors for QT prolongation, torsade de pointes (TdP), and/or sudden death such as cardiac arrhythmias, congenital long QT syndrome, heart failure, bradycardia, myocardial infarction, hypertension, coronary artery disease, hypomagnesemia, hypokalemia, hypocalcemia, or in patients receiving medications known to prolong the QT interval. Females, elderly patients, patients with diabetes mellitus, thyroid disease, malnutrition, alcoholism, or hepatic impairment may also be at increased risk for QT prolongation.
Renal failure, renal impairment
No dosage adjustment is required in patients with mild to severe renal impairment or end stage renal disease (ESRD). Due to increased exposure to pimavanserin in patients with severe renal impairment (CrCl less than 30 mL/minute), caution is advisable in patients with severe renal impairment, renal failure, or ESRD. In a renal impairment study, dialysis did not appear to significantly affect the concentrations of pimavanserin.
Dementia, geriatric, stroke
Pimavanserin, an atypical antipsychotic, is not approved for the treatment of patients with dementia-related psychosis unrelated to hallucinations and delusions associated with Parkinson’s disease psychosis. Atypical antipsychotic labels include a boxed warning indicating that geriatric patients with dementia-related psychosis treated with antipsychotics are at an increased risk of death. Of 17 placebo controlled trials performed in elderly patients with dementia-related psychosis receiving primarily atypical antipsychotics, the risk of death in the drug-treated patients was 1.6 to 1.7 times that of patients receiving placebo. Death typically occurred due to heart failure, sudden death, or infections (e.g., pneumonia). According to the Beers Criteria, antipsychotics are considered potentially inappropriate medications (PIMs) in elderly patients. Avoidance of antipsychotics is recommended in geriatric patients with the following disease states or symptoms due to the potential for exacerbation of the condition or increased risk of adverse effects: Parkinson’s disease (with some exceptions), delirium (possible new-onset or worsening delirium), and dementia (adverse CNS effects). There is an increased risk of stroke and greater rate of cognitive decline and mortality in persons with dementia receiving antipsychotics, and the Beers expert panel recommends avoiding antipsychotics to treat delirium- or dementia-related behavioral problems unless non-pharmacological options have failed or are not possible and the patient is a substantial threat to self or others. The Panel recommends avoiding antipsychotics in elderly patients with a history of falls or fractures, unless safer alternatives are not available, since antipsychotics can cause ataxia, impaired psychomotor function, syncope, and additional falls; if an antipsychotic must be used, consider reducing use of other CNS-active medications that increase the risk of falls and fractures and implement other strategies to reduce fall risk. Because antipsychotics can cause or exacerbate hyponatremia and SIADH and the elderly are at increased risk of developing these conditions, sodium levels should be closely monitored when starting or changing dosages of antipsychotics in older adults. The federal Omnibus Budget Reconciliation Act (OBRA) regulates the use of psychotropic medications, including antipsychotics, in residents of long-term care facilities. The OBRA guidelines provide criteria for use of psychotropic medications, requirements for medical record documentation of psychotropic drug use, monitoring parameters, and dosage guidance. Because pimavanserin has no appreciable affinity for dopaminergic receptors, the drug is considered less likely to induce extrapyramidal symptoms, however, in general, patients in skilled nursing facilities receiving any antipsychotic should have regular assessments for movement disorders and other antipsychotic side effects. Under OBRA guidelines, when antipsychotics are used without monitoring, they may be considered unnecessary medications because of inadequate monitoring.
Neonates, pregnancy
There are no data on pimavanserin use in pregnant women which would assist in determining drug-associated risks of major congenital malformations or miscarriage. Data obtained during the use of other antipsychotics during human pregnancy indicate that neonates exposed to antipsychotics during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms after delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder. Symptoms have ranged from self-limiting to those requiring hospitalization. Because pimavanserin has no appreciable affinity for dopaminergic receptors, the potential effects on newborns from in utero exposure, if any, are unknown. Nevertheless, neonates exhibiting possible signs or symptoms of extrapyramidal effects or withdrawal should be carefully monitored. The knowledge about long-term neurobehavioral effects in offspring is limited for all antipsychotic agents and requires further investigation. No adverse developmental effects were seen in animal reproduction studies during organogenesis at doses of pimavanserin up to 10- or 12-times the maximum recommended human dose (MRHD). Administration of pimavanserin to pregnant and lactating rats resulted in maternal toxicity and lower pup survival and body weight at doses that were 2 times the MRHD. The effects of pimavanserin during labor and delivery are unknown.
Breast-feeding
There is no information regarding the presence of pimavanserin in human breast milk. The developmental and health benefits of breast-feeding should be considered along with the mother’s clinical need for pimavanserin and any possible adverse effects on the infant from pimavanserin or from the underlying maternal condition. The American Academy of Pediatrics has previously considered some other antipsychotics (haloperidol, clozapine, etc.) to be drugs for which the effects on the nursing infant are not known but may be of concern, particularly with prolonged exposure. Use of antipsychotics during breast-feeding has been associated with drowsiness or lethargy in the infant and a decline in developmental scores. In addition, antipsychotics may cause hyperprolactinemia and galactorrhea to varying degrees, and thus may interfere with proper lactation. It should be noted that data related to the safety of antipsychotics during breast-feeding are limited and chronic administration of any antipsychotic during breast-feeding should be avoided if possible. Regardless of the antipsychotic used, the nursing infant should be closely monitored for excessive drowsiness, lethargy, and developmental delays. Combination treatment with antipsychotics may increase the risk of these adverse events. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. If a breast-feeding infant experiences an adverse effect related to a maternally administered drug, healthcare providers are encouraged to report the adverse effect to the FDA.
Children, infants
The safety and efficacy of pimavanserin in pediatric patients have not been established. Pimavanserin is not indicated for use in children or adolescents. There is no known use of this drug in infants.
ADVERSE REACTIONS:
Severe
stroke / Early / Incidence not known
Moderate
peripheral edema / Delayed / 7.0-7.0
confusion / Early / 6.0-6.0
hallucinations / Early / 5.0-5.0
constipation / Delayed / 4.0-4.0
edema / Delayed / Incidence not known
QT prolongation / Rapid / Incidence not known
Mild
nausea / Early / 7.0-7.0
infection / Delayed / 0-1.0
drowsiness / Early / Incidence not known
rash / Early / Incidence not known
urticaria / Rapid / Incidence not known
fatigue / Early / Incidence not known
Problem you have with that is the reality that all I did was post a news article and you created a delusion about me.
Not once mind you... but twice very recently.
Seriously dude You need help. You are showing a sever detachment from reality. Call someone today please. You really need to talk so someone about your mental health issues.
My supposed mental health issue is posting an article and you inventing delusions about me.
You don’t even respond to a personal post I make, but rather an article posted by me is good enough for you to make-up delusions.
I get it, you are the happy mental idiot who doesn’t want help.
Enjoy living under a bridge in the future.
I tried to help.
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.